ACLX News and Press, Arcellx Inc. From 09/15/22

The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Corporate Presentation - Slideshow

Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...

Summary Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts. Data shared in June for CART-ddBCMA in r/r multiple myeloma show...

Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology. This data will be out sometime next year. I covered Arcellx ( ACLX ) at its IPO in January. Arcellx is a clinical stage biopharma developing cancer immunothera...

Arcellx press release ( NASDAQ: ACLX ): Q2 GAAP EPS of -$0.88. cash, cash equivalents, and marketable securities of $307.0 million For further details see: Arcellx GAAP EPS of -$0.88

Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results PR Newswire -- Completed upsized follow-on offering of common stock, raising $128.8 million in gross proceeds including full exercise of underwriters' option to purchase additi...

Arcellx ( NASDAQ: ACLX ) shares are down 9% in late Wednesday afternoon trading. Today marks the end of the company's IPO lock-up period. Volume is slightly above the daily average of ~305.2K. As of 325p ET, ~401.4K shares had traded hands. Arcellx is focused on ca...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

For further details see: Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...